Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two leading scientists from the University of Oxford will join Professor Jonathan Van-Tam at this year’s Christmas Lectures by the Royal Institution.

Professors Teresa Lambe OBE and Katie Ewer © John Cairns

Professors Teresa Lambe OBE and Katie Ewer, who both played a key role in the UK’s response to the ongoing COVID-19 pandemic, will lead an on-screen exploration into their areas of scientific expertise.

They will aim to offer insights into the world of viruses – how they infect humans, and how humans respond – particularly in the context of vaccine development and infection control. They will also reveal why discoveries and advances made during the ongoing pandemic will have an impact far beyond COVID-19 and are set to change the future of medicine.

Prof Lambe is one of the Principal Investigators at the University of Oxford, overseeing the Oxford-AstraZeneca vaccine programme. From January 2020, she co-designed the vaccine, led the pre-clinical studies and then oversaw the delivery of the immune results needed to support regulatory approval of the vaccine in late 2020.

She said: ‘The Christmas Lectures are such a unique opportunity to share a passion for science, and to encourage young people to stay in science and to stay inquisitive. We need this enthusiasm, now more than ever, to tackle the big questions facing society.’

Professor Ewer is a cellular immunologist and Associate Professor at the Jenner Institute at the University of Oxford. During the pandemic, she has been an investigator on clinical trials of the Oxford/AZ vaccine, studying samples from volunteers to determine the strength of their cellular immune response to vaccination and how those responses relate to protection against COVID-19 infection.

Read the full story on the University of Oxford website

Similar stories

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

New tool aims to make bowel cancer treatments more effective

The Leedham Lab in Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Doug Higgs awarded the 2023 Genetics Society Medal

The award recognises Radcliffe Department of Medicine's Professor Higgs major contribution to our understanding of how mammalian genes are switched on and off, and using haematopoiesis as a model to understand how genes function.

First evidence drug resistant bacteria can travel from gut to lung, increasing infection risks

A new Oxford University study released during World Antimicrobial Awareness Week has significant findings on how antimicrobial resistance (AMR) arises and persists. The results, published today in Nature Communications, provide the first direct evidence of AMR bacteria migrating from a patient’s gut microbiome to the lungs, increasing the risk of deadly infections.